ClinicalTrials.gg
RecruitingNCT07688213TREMHANCEUpdated Nov 6, 2026

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

A Phase 2 interventional study of SAR448851 and Placebo in Dementia, Alzheimer's Type and Alzheimer's Disease, sponsored by Sanofi. Recruiting at 32 sites in 7 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Nov 6, 2026First sites in 5 new countriesNo longer in Japan+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Alzheimer Disease by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Sanofi.

Planned enrollment
7th of 11
160 · median 162
Started
2026
the only one that year
Phase 2
6 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Alzheimer Disease by Sanofi, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 2, and was the 11th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 11 studies in Alzheimer Disease by Sanofi is open now, in 7 countries.

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Sanofi, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology.

This Phase 2 study has 2 parts: Part A is a randomized, double-blind, parallel-group, placebo-controlled study with SAR448851 oral once daily. Part B is an open-label extension. All participants who complete Part A may continue to Part B. An optional dose 2 cohort will be considered to evaluate the efficacy and safety of SAR448851 dose 2 oral once daily.

The study duration will be up to 111 weeks for Part A and B, and up to 63 weeks for the dose 2 cohort. The treatment duration will be up to 96 weeks for Part A and B, and up to 48 weeks for the dose 2 cohort.

Up to 160 participants will be included in this study.

03

Conditions studied

  • Dementia, Alzheimer's Type
  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 55 to 85 years (inclusive) of age, at the time of signing the .
  • Diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) (National Institute on Aging-Alzheimer's Association [NIA-AA] Stage 3) or mild AD dementia (NIA-AA Stage 4).
  • Have a global Clinical Dementia Rating (CDR) score 0.5 to 1.0 and a CDR-Memory Box score ≥ 0.5 at screening.
  • Have a study partner who must provide separate written informed consent at screening. Study partner should be >18 years of age, have known participant for at least 1 year, and have a minimum of 8 hours per week contact with participant.
  • The participant has evidence of cerebral amyloid pathology confirmed by positive visual read on amyloid positron emission tomography (PET) at screening.

Exclusion criteria

Exclusion Criteria:

  • The participant has any history of significant neurological disease including but not limited to, frontotemporal dementia, Lewy body dementia, Huntington's disease, serious infection of the brain, Parkinson's disease, multiple concussions, multiple sclerosis, or epilepsy or recurrent seizures (except febrile childhood seizures).
  • The participant has evidence of more than 4 microhemorrhages (\<10 mm in diameter) or superficial siderosis.
  • The participant carries two copies of the apolipoprotein-E epsilon 4 (APOE4) allele (APOE4/4).
  • The participant is currently receiving or has previously received any anti-amyloid immunotherapy (including, but not limited to, aducanumab, lecanemab, or donanemab) or triggering receptor expressed on myeloid cells 2 (TREM-2) targeting therapy.
  • The participant is currently receiving anticoagulant therapies.
  • The participant has had in the 3 years prior to Screening, excluding basal cell carcinoma, squamous cell carcinoma of the skin, melanoma in situ, Stage 1 or 2 prostate cancer, fully resected renal cell cancers, or cervical carcinoma in situ that has been successfully treated.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    SAR448851

    Participants will receive SAR448851 dose 1 or dose 2 oral daily for 48 weeks

    Drug: SAR448851

  • Placebo comparator
    Placebo

    Participants will receive placebo oral daily for 48 weeks

    Drug: Placebo

Interventions

  • DrugSAR448851

    Pharmaceutical form: Capsule Route of administration: Oral

  • DrugPlacebo

    Pharmaceutical form: Capsule Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Part A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217

    Time frame: From baseline to Week 48

  2. Part B: Number of participants with treatment-emergent adverse events (TEAE), including ARIA-E and ARIA-H by brain MRI, laboratory assessments, vital sign measurements, ECGs and the C-SSRS

    Number of participants experiencing at least one treatment-emergent adverse event (TEAE), including amyloid-related imaging abnormalities with edema (ARIA-E) and amyloid-related imaging abnormalities with hemosiderin (ARIA-H) by brain magnetic resonance imaging (MRI), laboratory assessments, vital sign measurements, electrocardiograms (ECGs) and the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: From Week 48 to Week 96

Secondary outcomes

  1. Part A and optional dose 2 cohort: Change from baseline to Week 48 in plasma glial fibrillary acidic protein (GFAP) and cerebrospinal fluid (CSF) neurogranin (Ng)

    Time frame: From baseline to Week 48

  2. Part A and optional dose 2 cohort: Change from baseline to Week 48 in brain amyloid plaque deposition as measured by amyloid positron emission tomography (PET)

    Time frame: From baseline to Week 48

  3. Part A and optional dose 2 cohort: Change from baseline to Week 48 in CSF soluble triggering receptor expressed on myeloid cells 2 (sTREM2)

    Time frame: From baseline to Week 48

  4. Part A and optional dose 2 cohort: Number of participants with TEAEs and serious adverse events (SAEs), and discontinuations due to TEAEs and SAEs (including laboratory assessments, vital sign measurements, ECGs and the C-SSRS)

    Number of participants experiencing at least one treatment-emergent adverse event (TEAE), serious adverse event (SAE) or discontinuation due to TEAEs and SAEs (including laboratory assessments, vital sign measurements, electrocardiograms \[ECGs\] and the Columbia-Suicide Severity Rating Scale \[C-SSRS\])

    Time frame: From baseline to Week 48

  5. Part A and optional dose 2 cohort: Number of participants with ARIA-E and ARIA-H assessed by brain MRIs

    Number of participants with amyloid-related imaging abnormalities with edema (ARIA-E) and amyloid-related imaging abnormalities with hemosiderin (ARIA-H) assessed by brain magnetic resonance imaging (MRI). ARIA event: adverse event causing brain swelling or bleeding that requires close monitoring.

    Time frame: From baseline to Week 48

  6. Part A and optional dose 2 cohort: Plasma and CSF concentrations of SAR448851

    Time frame: From baseline to Week 48

  7. Part B: Change from baseline to Week 96 in AD biomarkers: plasma p-tau217, plasma GFAP, CSF Ng

    Change in Alzheimer's disease (AD) biomarkers: plasma p-tau217, plasma glial fibrillary acidic protein (GFAP) and cerebrospinal fluid (CSF) neurogranin (Ng)

    Time frame: From baseline to Week 96

  8. Part B: Change from Week 48 to Week 96 in AD biomarkers: plasma p-tau217, plasma GFAP, CSF Ng

    Change in Alzheimer's disease (AD) biomarkers: plasma p-tau217, plasma glial fibrillary acidic protein (GFAP) and cerebrospinal fluid (CSF) neurogranin (Ng)

    Time frame: From Week 48 to Week 96

07

Study locations

32 of 32 sites recruiting
  • Healthy Brain Clinic- Site Number : 8400011
    Long Beach, California 90804, United States
    Recruiting
  • Oakland Clinical- Site Number : 8400010
    Oakland, California 94609, United States
    Recruiting
  • Aqualane Clinical Research- Site Number : 8400001
    Naples, Florida 34105, United States
    Recruiting
  • K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008
    Orlando, Florida 32751, United States
    Recruiting
  • Alzheimer's Research and Treatment Center - Stuart, FL- Site Number : 8400014
    Stuart, Florida 34996, United States
    Recruiting
  • Axiom Brain Health- Site Number : 8400019
    Tampa, Florida 33609, United States
    Recruiting
  • Charter Research - Lady Lake- Site Number : 8400004
    The Villages, Florida 32162, United States
    Recruiting
  • Alzheimer's Research and Treatment Center - Wellington- Site Number : 8400012
    Wellington, Florida 33414, United States
    Recruiting
  • Boston Center for Memory - Newton- Site Number : 8400007
    Newton, Massachusetts 02459, United States
    Recruiting
  • The Cognitive and Research Center of New Jersey - Springfield- Site Number : 8400005
    Springfield, New Jersey 07081, United States
    Recruiting
  • Summit Research Network - Portland - Northwest Vaughn Street- Site Number : 8400002
    Portland, Oregon 97210, United States
    Recruiting
  • Flourish Research - Keystone Clinical Studies- Site Number : 8400003
    Plymouth Meeting, Pennsylvania 19462, United States
    Recruiting
  • Rhode Island Mood & Memory Research Institute- Site Number : 8400015
    East Providence, Rhode Island 02914, United States
    Recruiting
  • Kerwin Medical Center- Site Number : 8400006
    Dallas, Texas 75231, United States
    Recruiting
  • Investigational Site Number : 0360001
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
  • Investigational Site Number : 0360003
    Ivanhoe, Victoria 3081, Australia
    Recruiting
  • Investigational Site Number : 0360004
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Investigational Site Number : 1240001
    Ottawa, Ontario K1Z 1G3, Canada
    Recruiting
  • Investigational Site Number : 1240005
    Toronto, Ontario M4G 3E8, Canada
    Recruiting
  • Investigational Site Number : 1240008
    Montreal, Quebec H3H 1E8, Canada
    Recruiting
  • Investigational Site Number : 1560001
    Beijing, 100053, China
    Recruiting
  • Investigational Site Number : 2760003
    Berlin, 12203, Germany
    Recruiting
  • Investigational Site Number : 2760002
    Cologne, 50937, Germany
    Recruiting
  • Investigational Site Number : 7240008
    Barcelona, Barcelona [Barcelona] 08005, Spain
    Recruiting
  • Investigational Site Number : 7240006
    Barcelona, Barcelona [Barcelona] 08034, Spain
    Recruiting
  • Investigational Site Number : 7240004
    Barcelona, Catalunya [Cataluña] 08035, Spain
    Recruiting
  • Investigational Site Number : 7240003
    Pozuelo de Alarcón, Madrid 28223, Spain
    Recruiting
  • Investigational Site Number : 7240001
    Valencia, 46026, Spain
    Recruiting
  • Investigational Site Number : 7240005
    Zaragoza, 50012, Spain
    Recruiting
  • Investigational Site Number : 8260002
    London, Hammersmith and Fulham W6 8RF, United Kingdom
    Recruiting
  • Investigational Site Number : 8260001
    London, London, City of NW1 2BU, United Kingdom
    Recruiting
  • Investigational Site Number : 8260004
    Bath, Somerset BA1 3NG, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 7, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
23 sites added, 2 sites removed — first sites in Canada, Germany, Spain, United Kingdom and China; no longer in Japan
Show 23 added (6 United States, 6 Spain, 4 United Kingdom, 3 Canada, 2 Germany, 1 Australia, 1 China)
  • Healthy Brain Clinic- Site Number : 8400011 · Long Beach, United States
  • K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008 · Orlando, United States
  • Investigational Site Number : 0360003 · Ivanhoe, Australia
  • Investigational Site Number : 1240001 · Ottawa, Canada
  • Investigational Site Number : 2760002 · Cologne, Germany
  • Investigational Site Number : 7240003 · Pozuelo de Alarcón, Spain
  • Investigational Site Number : 8260002 · London, United Kingdom
  • Investigational Site Number : 8260001 · London, United Kingdom
  • Investigational Site Number : 8260003 · London, United Kingdom
  • Investigational Site Number : 8260004 · Bath, United Kingdom
  • Alzheimer's Research and Treatment Center - Stuart, FL- Site Number : 8400014 · Stuart, United States
  • Axiom Brain Health- Site Number : 8400019 · Tampa, United States
  • Alzheimer's Research and Treatment Center - Wellington- Site Number : 8400012 · Wellington, United States
  • Rhode Island Mood & Memory Research Institute- Site Number : 8400015 · East Providence, United States
  • Investigational Site Number : 1240005 · Toronto, Canada
  • Investigational Site Number : 1240008 · Montreal, Canada
  • Investigational Site Number : 1560001 · Beijing, China
  • Investigational Site Number : 2760003 · Berlin, Germany
  • Investigational Site Number : 7240008 · Barcelona, Spain
  • Investigational Site Number : 7240006 · Barcelona, Spain
  • Investigational Site Number : 7240004 · Barcelona, Spain
  • Investigational Site Number : 7240001 · Valencia, Spain
  • Investigational Site Number : 7240005 · Zaragoza, Spain
Show 2 removed
  • Investigational Site Number : 3920001 · Kurashiki, Japan
  • Investigational Site Number : 8260003 · London, United Kingdom
across 2 updates, Oct 23, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    13 sites added, 1 site removed — first site in China
    Show 13 added (5 Spain, 4 United States, 2 Canada, 1 China, 1 Germany)
    • Alzheimer's Research and Treatment Center - Stuart, FL- Site Number : 8400014 · Stuart, United States
    • Axiom Brain Health- Site Number : 8400019 · Tampa, United States
    • Alzheimer's Research and Treatment Center - Wellington- Site Number : 8400012 · Wellington, United States
    • Rhode Island Mood & Memory Research Institute- Site Number : 8400015 · East Providence, United States
    • Investigational Site Number : 1240005 · Toronto, Canada
    • Investigational Site Number : 1240008 · Montreal, Canada
    • Investigational Site Number : 1560001 · Beijing, China
    • Investigational Site Number : 2760003 · Berlin, Germany
    • Investigational Site Number : 7240008 · Barcelona, Spain
    • Investigational Site Number : 7240006 · Barcelona, Spain
    • Investigational Site Number : 7240004 · Barcelona, Spain
    • Investigational Site Number : 7240001 · Valencia, Spain
    • Investigational Site Number : 7240005 · Zaragoza, Spain
    Show 1 removed
    • Investigational Site Number : 8260003 · London, United Kingdom
    + 1 other change: verification date
  2. Oct 23, 2026
    10 sites added, 1 site removed — first sites in Canada, Germany, Spain and United Kingdom; no longer in Japan
    Show 10 added (4 United Kingdom, 2 United States, 1 Australia, 1 Canada, 1 Germany, 1 Spain)
    • Healthy Brain Clinic- Site Number : 8400011 · Long Beach, United States
    • K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008 · Orlando, United States
    • Investigational Site Number : 0360003 · Ivanhoe, Australia
    • Investigational Site Number : 1240001 · Ottawa, Canada
    • Investigational Site Number : 2760002 · Cologne, Germany
    • Investigational Site Number : 7240003 · Pozuelo de Alarcón, Spain
    • Investigational Site Number : 8260002 · London, United Kingdom
    • Investigational Site Number : 8260001 · London, United Kingdom
    • Investigational Site Number : 8260003 · London, United Kingdom
    • Investigational Site Number : 8260004 · Bath, United Kingdom
    Show 1 removed
    • Investigational Site Number : 3920001 · Kurashiki, Japan
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07688213
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Jul 28, 2026
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion